Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report

Li, Jing; Chen, Gang; Zhang, Mingmin; Tu, Shenghao; Chen, Chao

doi:10.1186/s12879-020-05434-4

Cited by 7 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 . Most included studies were case reports (n=89) [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] ...…”

Section: Resultsunclassified

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Quante

Brake

Tolios

et al. 2021

Transplantation Proceedings

View full text Add to dashboard Cite

Background : The SARS-CoV-2 pandemic is challenging health systems all over the world. Particularly high-risk groups show considerable mortality rates after infection. In 2020, an inexorable number of case reports, case series and ultimately various systematic reviews have been published reporting on morbidity and mortality risk of SARS-CoV-2 in solid organ transplant (SOT) recipients. However, this vast array of publications resulted in an increasing complexity of the field, overwhelming even the expert reader. Methods : We performed a structured literature review comprising electronic databases, transplant journals and included literature from previous systematic reviews covering the entire year 2020. From 164 included articles we identified 3451 cases of SARS-CoV-2 infected SOT recipients. Results : Infections resulted in a hospitalization rate of 84% and 24% intensive care unit admissions (ICU) in the included patients. Whereas 53.6% of patients were reported to have recovered, cross-sectional overall mortality reported after COVID-19 was at 21.1%. Synoptic data concerning immunosuppressive medication attested to the reduction or withdrawal of antimetabolites (81.9%) and calcineurin inhibitors (48.9%) as a frequent adjustment. In contrast, steroids were reported to be increased in 46.8% of SOT patients. Conclusions : COVID-19 in SOT recipients is associated with high morbidity and mortality worldwide. Conforming with current guidelines, modifications of immunosuppressive therapies mostly comprised a reduction or withdrawal of antimetabolites and calcineurin inhibitors, while frequently maintaining or even increasing steroids. Here, we provide an accessible overview to the topic and synoptic estimates of expectable outcomes regarding in-hospital mortality of SOT patients diseased with COVID-19.

show abstract

Section: Resultsunclassified

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Quante

Brake

Tolios

et al. 2021

Transplantation Proceedings

View full text Add to dashboard Cite

show abstract

“…A total of 178 studies were found to have reported IFNα treatment for COVID-19 (Supplemental 2). [13] , [17] , [19] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , …”

Section: Comprehensive Review Of the Literature On The Safety And Efficacy Of Interferon Alpha Treatment In Covid-19 Patientsunclassified

“…The use of IFNα inhalation was reported in patients with various comorbidities and conditions, including patients with atopic dermatitis, [38] allergic rhinitis, [38] bronchiolitis, [25] chronic obstructive pulmonary disease, [84] , [162] tuberculosis, [55] cardiovascular disease, [22] hypertension, [22] , [84] , [150] , [162] diabetes, [32] , [39] hyperlipidemia, [150] obesity, [126] metabolic syndrome, [192] chronic hepatitis B infection, [76] , [153] chronic kidney disease, [22] , [70] malignancy, [163] liver transplant, [50] kidney transplant, [70] , [172] and pregnancy. [19] The use of subcutaneous injection of IFNα was reported in patients with diabetes, [42] hypertension, [42] , [44] hyperlipidemia, 42 chronic hepatitis B infection, [140] primary myelofibrosis with macrocytic anemia, [44] dementia, [44] chronic kidney disease, [44] Behcet's disease, [190] and osteoporosis.…”

Section: Comprehensive Review Of the Literature On The Safety And Efficacy Of Interferon Alpha Treatment In Covid-19 Patientsmentioning

confidence: 99%

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Lu¹,

Feng²,

Yu³

et al. 2022

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1 st , 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.

show abstract

“…It may have a severe clinical course, while some patients may experience no significant clinical symptoms (2). Severe lung damage and other complications that lead to organ failure in COVID-19 could result from a dysregulated immune system response (3).…”

Section: Introductionmentioning

confidence: 99%

A renal transplant patient with covid-19 disease presented with acute cellular rejection

Soleimani,

Mohammadzadeh

2024

Preprint

View full text Add to dashboard Cite

show abstract

Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report

Cited by 7 publications

References 31 publications

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

A renal transplant patient with covid-19 disease presented with acute cellular rejection

Contact Info

Product

Resources

About